Merck & Co.’s first-in-class HIF-2 alpha inhibitor Welireg is touching down in the clear cell renal cell carcinoma (ccRCC) | ...
IQVIA Digital has developed technology to help pharma marketers identify nurse practitioners (NPs) and physician associates ...
In patients with BTK-pretreated chronic lymphocytic leukemia (CLL), AbbVie and Roche’s Venclexta (venetoclax) is the drug to ...
Eisai snares government manufacturing grant as it brings Leqembi packaging to UK with $65M expansion
As the United Kingdom juggles industry concerns about the region’s waning appeal and competitiveness, Eisai is getting a lift from a production-tinged fund that the British government first unveiled ...
An independent research firm is reviewing data on Amgen’s Tavneos as the company prepares for a hearing with the FDA which ...
In a plenary session at the 2026 European Hematology Association (EHA) annual meeting in Stockholm, Johnson & Johnson brought ...
While patients in Novo trials don't need to take any action, the company recommends patients "remain vigilant and report to ...
The accelerated approval for Jazz Pharmaceuticals’ small cell lung cancer (SCLC) drug Zepzelca may once again be in jeopardy.
Staring down a $6 billion patent cliff for its prostate cancer drug Xtandi, Astellas aims to counter the inevitable revenue ...
Gilead’s lenacapavir has been on the market since 2022, when it was approved in the U.S. as Sunlenca for twice-yearly ...
The LinkedIn activities of AstraZeneca employees have yet again landed the drugmaker in hot water, with the U.K. marketing ...
With a resounding unanimous vote, the U.S. Supreme Court has sided with Hikma Pharmaceuticals, ruling that its generic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results